GlassScriptPhysician profile
Jeanne P Osborn
NPI 1013994367
$2,451.54
in general payments reported to CMS, 2019-2025
20 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $75.31 · 2021: $149 · 2022: $448 · 2023: $260 · 2024: $399 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.58 | 2019-2025 | |
| Janssen Biotech, INC. | $269.27 | 2019-2025 | Tremfya |
| Incyte Corporation | $261.56 | 2022-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $238.08 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $198.90 | 2019-2025 | Dupixent |
| Almirall LLC | $149.41 | 2021 | |
| Pfizer INC. | $116.56 | 2025 | |
| Lilly USA, LLC | $87.43 | 2019-2025 | Ebglyss |
| Regeneron Pharmaceuticals, INC. | $61.23 | 2022 | |
| Genzyme Corporation | $56.57 | 2019-2025 | |
| Amgen INC. | $50.51 | 2019-2024 | Otezla |
| Dusa Pharmaceuticals, INC. | $45.02 | 2019 | |
| Ucb, INC. | $44.50 | 2019-2024 | Bimzelx |
| Mylan Pharmaceuticals INC. | $33.08 | 2019 | |
| Epi Health, LLC | $25.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $22.45 | 2020 | |
| Arcutis Biotherapeutics, INC. | $18.68 | 2025 | Zoryve |
| Organon LLC | $16.56 | 2025 | Vtama |
| Botanix Sb INC | $14.19 | 2025 | Sofdra |
| Genentech USA, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.